ASH 2022 Conference Coverage
ASH 2022 Phase I Dose-Escalation Study of Forimtamig (RG6234), a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody in R/R MM: Updated IV and First SC Results
By
ASH 2022 Conference Coverage
FEATURING
Carmelo Carlo-Stella
By
ASH 2022 Conference Coverage
FEATURING
Carmelo Carlo-Stella
Login to view comments.
Click here to Login